-

Dr. Fu Fu Zheng: New Advances in Prostate Cancer Research at the 2024 ASCO Meeting (Real-World Exploration and Learning from Others)
Prostate cancer is a common malignant tumor of the reproductive system, particularly affecting elderly men. Screening high-risk populations and tailoring treatment plans based on patient characteristics are crucial for improving cure rates and enhancing quality of life. Recently, the 2024 ASCO Annual Meeting unveiled numerous advancements in the treatment of prostate cancer. “Oncology Frontier” invited…
-

2024 COMB丨Dr. Tao Sun: Progress in HER2+ EBC Treatment—De-escalation Therapy and the Prospects of ctDNA Application
In recent years, the field of breast cancer treatment has seen a series of innovative research advancements, particularly in the treatment of HER2+ early breast cancer (EBC). Strategies such as “de-escalation,” “chemotherapy-free,” and “precision treatment” have become hot topics. At the 7th Precision Diagnosis and Treatment of Tumors and the 10th Individualized Treatment of Breast…
-

ASCO GU Researcher Speaks丨Professor St-Laurent: Urinary Tumor DNA Detects Minimal Residual Disease, Aiding in Extended Patient Survival
The ASCO-GU 2024, a major event in the field of urologic oncology, was held in San Francisco, USA, showcasing numerous innovative research advancements and discussing future treatment directions for urologic and male reproductive system tumors. For patients with non-muscle invasive bladder cancer (NMIBC) who do not respond to Bacillus Calmette-Guérin (BCG) treatment, there remains a…
-

EHA International Perspective | Professor Thierry Facon: Major Advances in Multiple Myeloma Treatment—Insights from the IMROZ Study
Despite significant improvements in the survival of multiple myeloma (MM) patients over the past two decades, thanks to the emergence of new drugs and therapies, the prognosis for those not eligible for bone marrow transplantation remains relatively poor. Therefore, there is an urgent need to explore new treatment options to improve their outcomes. At the…



